B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

RAF1

MOLECULAR TARGET

Raf-1 proto-oncogene, serine/threonine kinase

UniProt: P04049NCBI Gene: 589428 compounds

RAF1 (Raf-1 proto-oncogene, serine/threonine kinase) is targeted by 28 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting RAF1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1imatinib5.47236
2sb 2035804.92136
3foretinib4.3476
4nilotinib4.1764
5pi 1034.1764
6doramapimod4.0657
7pazopanib3.6939
8sb 2021903.6437
9regorafenib3.5634
10dabrafenib3.3026
11gw305074x3.1422
12ci 10402.9418
13r 4062.8316
14plx 47202.7114
15ast 4872.5612
16raf 2652.4811
17motesanib2.4811
18sb5908852.4010
19avutometinib2.309
20rebastinib2.208
21ly 30091202.087
22osi 9302.087
23cep 324961.956
24sns 314 mesylate1.956
25naporafenib1.956
26Sorafenib1.102
27Vemurafenib1.102
28Dasatinib0.691

About RAF1 as a Drug Target

RAF1 (Raf-1 proto-oncogene, serine/threonine kinase) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 28 compounds with documented RAF1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

RAF1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.